http://www.minervamedica.it/en/journals/minerva-urologica-nefrologica/article.php?cod=R19Y9999N00A16090102
- 1U.O di Urologia I.N.T. Fondazione Pascale di Napoli, Naples, Italy - Giuseppe.quarto@gmail.com.
Abstract
BACKGROUND:
The
relationship between lower urinary tract symptoms (LUTS) and erectile
dysfunction (ED) has received increased attention recently. This study
aims to evaluate the efficacy of IDIProst® Gold, a product containing
Serenoa repens, Crocus sativus
and PMBE (Pinus massoniana bark extract), in improving sexual function,
urinary symptoms and quality of life in patients with concomitant LUTS
and ED.
METHODS:
140 men (mean age 48 years) were enrolled and treated in this study. All patients were administered IDIProst® Gold (Crocus sativus,
PMBE, Serenoa repens) once daily for three months. At visit (T0) and
after ninety days of treatment (T90), the patients were evaluated and
asked to complete three self-administered questionnaires: IPSS
(International Prostate Symptoms Score), IIEF-5 (International Index of
Erectile Function) and SF-36 (Short Form Health Survey). The main
outcomes were the improved IIEF-5 and IPSS scores in the 40‒60 age
group. The secondary outcome was the improved quality of life score
among treated patients.
RESULTS:
The
baseline mean scores at T0 were 17.29 and 15.12 for the IPSS and IIEF-5
respectively. After three months of treatment (T90), the questionnaire
results were as follows: 10.21 and 20.53 for IPSS and IIEF-5
respectively. Statistically significant differences (p<0.001) were
reported between the two visits in terms of IPSS and IIEF-5 for all the
groups treated, but particularly the 40‒60 age group. There was also a
statistically significant improvement (p<0.001) in quality of life
between T0 and T90 (3.82 vs. 1.45). Compliance with the study protocol
was 100%. 140 patients were enrolled out of a population of 164. No
adverse events were reported.
CONCLUSIONS:
Treatment once daily with IDIProst® Gold (Serenoa repens, Crocus sativus
and PMBE) for three months significantly improved sexual function,
urinary symptoms and quality of life in patients with concomitant LUTS
and ED, especially in the 40‒60 age group.
